{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Tan J"],"funding":["\"Yun He\" Talent Project of Tongzhou District, Beijing","Science and Technology Project of Tongzhou District, Beijing"],"pagination":["e70838"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11976457"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(7)"],"pubmed_abstract":["<h4>Background</h4>Epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma (LUAD) is the most common subtype among non-small cell lung cancer (NSCLC) and targeted therapies are the primary approach for treatment. However, the development of resistance to therapy and histological transformation into small cell lung cancer (SCLC) present significant challenges. Understanding the mechanisms underlying this transformation is crucial for effective differential diagnosis and the formulation of treatment strategies.<h4>Methods</h4>In this study, we collected tissue from 5 primary LUAD before SCLC transformation, 12 transformed SCLC after EGFR tyrosine kinase inhibitor (TKI) treatment, and 18 de novo SCLC from lung cancer patients treated at Beijing Chest Hospital, Capital Medical Univ"],"journal":["Cancer medicine"],"pubmed_title":["Whole Exome Sequencing Study Identifies Distinct Characteristics of Transformed Small Cell Lung Cancer With EGFR Mutation Compared to De Novo Small Cell and Primary Non-Small Cell Lung Cancers."],"pmcid":["PMC11976457"],"funding_grant_id":["YHLD2019039","YHLJ202021","KJ2021CX009"],"pubmed_authors":["Peng Y","Li X","Li J","Zheng H","Wang Q","Hu Y","Tan J","Zhao D","Che N"],"additional_accession":[]},"is_claimable":false,"name":"Whole Exome Sequencing Study Identifies Distinct Characteristics of Transformed Small Cell Lung Cancer With EGFR Mutation Compared to De Novo Small Cell and Primary Non-Small Cell Lung Cancers.","description":"<h4>Background</h4>Epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma (LUAD) is the most common subtype among non-small cell lung cancer (NSCLC) and targeted therapies are the primary approach for treatment. However, the development of resistance to therapy and histological transformation into small cell lung cancer (SCLC) present significant challenges. Understanding the mechanisms underlying this transformation is crucial for effective differential diagnosis and the formulation of treatment strategies.<h4>Methods</h4>In this study, we collected tissue from 5 primary LUAD before SCLC transformation, 12 transformed SCLC after EGFR tyrosine kinase inhibitor (TKI) treatment, and 18 de novo SCLC from lung cancer patients treated at Beijing Chest Hospital, Capital Medical Univ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-06-01T21:59:54.715Z","creation":"2025-07-01T03:05:10.655Z"},"accession":"S-EPMC11976457","cross_references":{"pubmed":["40197849"],"doi":["10.1002/cam4.70838"]}}